Clinically meaningful blood pressure reduction across 7,000 patients*2,3
The SPYRAL HTN Clinical Program features the most rigorous and extensive patient experience as shown in multiple clinical trials and the largest real-world patient registry.1,4-7
Data from randomized controlled trials
The Symplicity blood pressure procedure has demonstrated signifcant, safe and sustained blood pressure reductions in randomized controlled trials.1,4-6
Largest real-world registry
The GLOBAL SYMPLICITY REGISTRY, which includes a cross-section of high-risk patient subgroups, has shown blood pressure reductions between -10 and -20 mmHg out to three years.7
Unmatched clinical evidence
The Symplicity blood pressure procedure is supported by published clinical evidence unmatched in scope, quantity, and quality.
Learn about the procedure
Explore CME courses, peer presentations, and other educational content about the Symplicity blood pressure procedure.
Take action on hypertension
Gain access to resources to introduce the Symplicity blood pressure procedure to your community successfully.
*
Patients enrolled in Medtronic-sponsored, funded or physician-initiated studies.
†
In typical uncontrolled hypertension patients.
‡
ANCOVA adjusted; secondary efficacy analysis.
§
RDN arm reduction from baseline.
||
Death, stroke, end-stage renal disease, or MI.
1
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. The Lancet 2020; Published online March 29, 2020. DOI: 10.1016/ S0140-6736(20)30554-7.
2
Lewington S. Age-specifc relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet. 2002;360(9349):1903-1913.
3
Data on file, Medtronic. April 2021.
4
Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. The Lancet. 2022; 399:1401-1410.
5
Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet. 2018;391:2346–2355.
6
Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. The Lancet. 2017;390(10108):2160–2170.
7
Mahfoud F, Mancia G, Schmieder R, et al. Three-year safety and efficacy in the Global Symplicity Registry: Impact of antihypertensive medication burden on blood pressure reduction. Presented at PCR e-course 2020.